Kazakhstan vs Mexico: Access to anti-retroviral drugs, female
Kazakhstan
60.0%
in 2024
Mexico
58.0%
in 2024
Kazakhstan rank
103rd
Mexico rank
105th
Access to anti-retroviral drugs, female over time
- Kazakhstan
- Mexico
How they compare
Kazakhstan currently reports 60.0% against 58.0% in Mexico, a difference of 2.0%.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Mexico ahead.
Kazakhstan ranks 103rd and Mexico ranks 105th of 141 countries.
Mexico has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Kazakhstan | Mexico | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.3% | 19.2% | 17.9% | Mexico |
| 2010s | 21.3% | 44.6% | 23.3% | Mexico |
| 2020s | 54.0% | 58.6% | 4.6% | Mexico |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Kazakhstan or Mexico?
- Kazakhstan, at 60.0% against 58.0% in Mexico as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Kazakhstan and Mexico?
- 2.0%, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Mexico?
- 25 years are reported by both, from 2000 to 2024.
- How do Kazakhstan and Mexico rank globally for access to anti-retroviral drugs, female?
- Kazakhstan ranks 103rd and Mexico ranks 105th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.